Analytical and Clinical Validation of a Target-Enhanced Whole Genome Sequencing-Based Comprehensive Genomic Profiling...

Area of Science:

• Oncology
• Genomics
• Molecular Diagnostics

Background:

• Comprehensive genomic profiling is crucial for personalized cancer treatment.
• Existing targeted panels may not capture the full spectrum of genomic alterations.
• Whole-genome sequencing offers a more extensive approach to identifying biomarkers.

Purpose of the Study:

• To evaluate the analytical and clinical performance of the Target enhanced whole-genome sequencing (TE-WGS) assay.
• To assess the assay's accuracy in detecting single nucleotide variants (SNVs), insertions/deletions (indels), and structural variants (SVs).
• To compare TE-WGS performance against established orthogonal methods for oncology genomic profiling.

Main Methods:

• Analytical validation including sensitivity, specificity, and positive predictive value (PPV) for SNVs, indels, and SVs.
• Clinical validation by benchmarking against orthogonal methods.
• Comprehensive analysis of both germline and somatic findings across the entire genome.

Main Results:

• TE-WGS achieved a sensitivity of 99.8% for SNVs and 99.2% for indels.
• The assay demonstrated a PPV of 99.3% for SNVs and 98.7% for indels.
• High concordance was observed between TE-WGS and reference methods during clinical validation.

Conclusions:

• TE-WGS is a highly accurate and reliable assay for comprehensive oncology genomic profiling.
• The assay provides broader genomic insights compared to traditional targeted panels.
• TE-WGS effectively identifies key biomarkers and both germline and somatic alterations.